Results 201 to 210 of about 94,881 (302)

Electrophysiological and Psychological Correlates of Cognition in Adult Homozygous Sickle Cell Disease Patients. [PDF]

Ann Neurosci
Sahu T, Sinha M, Sinha R, Wasnik P, Ingle A, Tikka SK.   +5 more
europepmc   +1 more source

Anti‐Inflammatory, Antioxidant, Molecular Docking and Pharmacokinetics Properties of Cycloeucalenone Isolated From Musa × paradisiaca L. Fruit Peels

Chemistry &Biodiversity, Volume 23, Issue 1, January 2026.
ABSTRACT This study isolated a compound with anti‐inflammatory properties from Musa × paradisiaca fruit peels. The methanol extract was partitioned, and the hexane fraction with the best bioactivity was subjected to column chromatography before characterization via Fourier transform infrared (FTIR), UV–visible (UV–VIS) and NMR analysis.
Ibeabuchi J. Ali, Kolawole A. Olofinsan, Goodnews O. Ikeh, Ndidiamaka H. Okorie, Cyril C. Adonu, Romanus C. Omeh, Blessing C. Idoko, Pamela E. Nnamani   +7 more
wiley   +1 more source

Human Protein Z as the Second Known Heme‐Binding Protein from the Endogenous Blood Coagulation Inhibitor System

ChemBioChem, Volume 27, Issue 1, January 2026.
Protein Z is a vitamin K‐dependent anticoagulant with elusive molecular functions. Herein, it is shown that heme binds to protein Z and induces conformational changes. One histidine‐based heme‐binding motif is identified. High heme‐binding affinity and functional effects are demonstrated on protein level. These findings shed new light on the structural
Paula Lindemann, Marie‐T. Hopp
wiley   +1 more source

Acoustic probing of new biomarkers for rapid sickle cell disease screening.

Lab Chip
Sridhar N, Song M, Stowell MHB, Hassell KL, Ding X.   +4 more
europepmc   +1 more source

Safety, Pharmacokinetics, and Pharmacodynamics of Osivelotor for Sickle Cell Disease: First‐in‐Human Studies in Healthy Participants and Patients

Clinical Pharmacology &Therapeutics, Volume 119, Issue 1, Page 120-130, January 2026.
The investigational agent osivelotor, a small molecule hemoglobin (Hb) modifier in development for the treatment of sickle cell disease (SCD), acts by increasing Hb‐oxygen affinity and inhibiting the polymerization of sickle Hb. We report safety, pharmacokinetic (PK), and pharmacodynamic (PD) data from the first two phase 1 clinical trials of ...
Eleanor A. Lisbon, R. Clark Brown, Andrew Redfern, Ken Duchin, Aline Barth, Erika S. Roberts, Polo Gaputan, Kobina Dufu, Arthur Lo, Mira Patel Pochron, David R. Archer, Wai Chin, Karena Kong, Carla B. Washington, Adeyemi Adenola, Eric I. Zimmerman   +15 more
wiley   +1 more source

UHRF2 as a genetic correlate of hospitalization in sickle cell disease. [PDF]

Br J Haematol
Cintho Ozahata M, Oliveira M, Gomes I, Maximo C, Ferraz A, Belisário AR, Souza D, Braga NA, Sabino E, Custer B, Kelly S, Dinardo CL, REDS‐III Brazil SCD Cohort study and the TOPMed consortium.   +12 more
europepmc   +1 more source

Transcriptomic Responses of the Marine Diatom Phaeodactylum tricornutum to High Carbon and Low Nitrogen Stress

Ecology and Evolution, Volume 16, Issue 1, January 2026.
To elucidate the integrated transcriptional mechanisms underlying diatom acclimation to coupled carbon–nitrogen (CN) imbalance, we employed RNA sequencing (RNA‐Seq) to characterize the global transcriptional response of the model diatom Phaeodactylum tricornutum to high CO2 (~2000 μatm) and low nitrogen (10% of nitrogen concentration in f/2 medium ...
Yi Zhang, Jiawen Duan, Yimeng Zheng, Xiaoqi Chen, Chenhui Li, Zhenyu Xie, Aiyou Huang   +6 more
wiley   +1 more source

"We Cure Sickle Cell Disease with Herbs": Perspectives of Herbal Medicine Practitioners Treating Sickle Cell Disease in the Acholi Sub-Region. [PDF]

J Multidiscip Healthc
Awor S, Opee J, Ocaya D, Ocaya J, Abola B, Malinga GM, Oryema C, Arwenyo B, Ongwech A, Musoke D, Nnamuyomba P, Epila J.   +11 more
europepmc   +1 more source

MeMAGEN: A Phase IIa/IIb open‐label trial of memantine testing safety and tolerability in sickle cell patients

HemaSphere, Volume 10, Issue 1, January 2026.
ABSTRACT Administration of memantine, an antagonist of the N‐methyl‐ d‐aspartate receptor, prevents Ca2+ overload and dehydration of red blood cells (RBCs) in patients with sickle cell disease (SCD). The objectives of the 1‐year dose‐escalation Phase IIa/IIb Memantine trial (MeMAGEN – NCT 03247218) with 17 SCD patients who were under stable ...
Ariel Koren, Carina Levin, Leonid Livshits, Fabio Valeri, Sari Peretz, Sivan Raz, Anna Yu Bogdanova, Max Gassmann   +7 more
wiley   +1 more source